Biogen Price to Sales Ratio 2010-2022 | BIIB

Historical PS ratio values for Biogen (BIIB) over the last 10 years. The current P/S ratio for Biogen as of July 01, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Biogen P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-07-01 210.63 2.90
2022-03-31 210.60 $72.62 2.90
2021-12-31 239.92 $73.15 3.28
2021-09-30 282.99 $72.56 3.90
2021-06-30 346.27 $75.34 4.60
2021-03-31 279.75 $79.73 3.51
2020-12-31 244.86 $82.46 2.97
2020-09-30 283.68 $84.37 3.36
2020-06-30 267.55 $82.43 3.25
2020-03-31 316.38 $78.55 4.03
2019-12-31 296.73 $75.85 3.91
2019-09-30 232.82 $73.43 3.17
2019-06-30 233.87 $70.92 3.30
2019-03-31 236.38 $68.12 3.47
2018-12-31 300.92 $65.19 4.62
2018-09-30 353.31 $63.54 5.56
2018-06-30 290.24 $61.04 4.75
2018-03-31 273.82 $59.35 4.61
2017-12-31 318.57 $57.58 5.53
2017-09-30 313.12 $55.18 5.67
2017-06-30 271.36 $54.12 5.01
2017-03-31 273.42 $52.81 5.18
2016-12-31 261.39 $52.22 5.01
2016-09-30 288.53 $51.38 5.62
2016-06-30 222.89 $49.85 4.47
2016-03-31 239.95 $47.65 5.04
2015-12-31 282.37 $46.06 6.13
2015-09-30 268.35 $44.92 5.97
2015-06-30 372.33 $43.57 8.55
2015-03-31 389.19 $42.78 9.10
2014-12-31 312.88 $40.88 7.65
2014-09-30 304.92 $38.00 8.02
2014-06-30 290.63 $35.07 8.29
2014-03-31 281.93 $32.09 8.79
2013-12-31 257.69 $29.08 8.86
2013-09-30 221.92 $26.74 8.30
2013-06-30 198.36 $24.89 7.97
2013-03-31 177.54 $23.58 7.53
2012-12-31 134.91 $22.98 5.87
2012-09-30 137.53 $22.48 6.12
2012-06-30 133.08 $22.00 6.05
2012-03-31 116.14 $21.03 5.52
2011-12-31 101.44 $20.61 4.92
2011-09-30 85.86 $19.98 4.30
2011-06-30 98.55 $19.49 5.06
2011-03-31 67.72 $19.19 3.53
2010-12-31 61.80 $18.34 3.37
2010-09-30 51.73 $17.45 2.96
2010-06-30 43.74 $16.44 2.66
2010-03-31 52.90 $15.58 3.40
2009-12-31 49.31 $15.09 3.27
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $30.847B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00